Suzanne Elvidge

Suzanne Elvidge
Suzanne Elvidge

Suzanne Elvidge has been involved in biopharma science and business publishing and journalism for over twenty years. She became the editor of FierceBiomarkers in November 2011, and has also written for FierceVaccines and FierceDrugDelivery. As a freelance writer she has written news and features for a range of online and print publications including European Life Science, the Journal of Life Sciences (now the Burrill Report), In Vivo, Life Science Leader, Nature Biotechnology, PR Week and Start-Up. She is also the editor of Genome Engineering, a blog that monitors the latest developments in genome engineering. She lives in the Peak District, in a very rural part of Derbyshire, U.K., with her second-hand bookseller husband and two second-hand cats. She can be reached at [email protected]. Follow @suzannewriter on Twitter.

Stories by Suzanne Elvidge

Addex approaches the clinic for rare dystonias

Addex Therapeutics' dipraglurant, in the clinic for Parkinson's disease, also has potential in a number of rare dystonias, according to preclinical data announced this week, and Phase II clinical trials could begin as early as the second half of 2013.

Troubled BioCryst dumps HCV preclinical program

In a piece of news tucked away in its Form 8-K, troubled BioCryst Pharmaceuticals has ditched its preclinical hepatitis C virus (HCV) program of BCX5191 and its backup compounds following results of a low-dose chimpanzee study.

Stem cells help rats recover from stroke

Strokes can be devastating, and even when patients are treated with clot-busters within an hour, some of the damage can be irreversible. But there may be hope in stem cells—in rats, these brain and nerve damage after a stroke, returning the animals to near normal within just a couple of weeks.

Particles with a heart of gold attack lymphoma without drugs

If Northwestern Medicine's mouse studies come good, then in the future, doctors could treat lymphoma without toxic drugs with something as simple as minute particles of gold. These block the entry of HDL cholesterol and starve the cancer cells to death, according to new research in PNAS.